Navigation Links
GVAX in Medical News

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...

Experimental Cancer Vaccines Show Promise

...ented Tuesday at the American Association for Cancer Research annual meeting, in San Diego. A second study, out of the Netherlands, found that the gvax vaccine stimulated a significant immune response in men with prostate cancer. Five out of six participants receiving the highest dose of vaccine showe...

Immunotherapy: enlisting the immune system to fight cancer

...ic hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilumumab: ...phase I trial, they observed that a combination of gvax immunotherapy with ipilimumab lowered prostate-spe...s. Higher doses of ipilimumab combined with the gvax vaccine is showing a lot of success in increasing ...

Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

... potential association between immune responses to gvax immunotherapy for prostate cancer and increase...irst of two ongoing Phase 3 clinical trials of gvax immunotherapy for prostate cancer, completed a ... Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials ...

Combo Treatment Best for Melanoma, Advanced Ovarian Cancer

...ce a protein called GVAX. When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting a more energetic attack o...mune response spurred by the vaccine, researchers studied whether combining gvax vaccines with monoclonal antibody therapy could lengthen remissions and que...

Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer

... When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting ... researchers have begun studying whether combining gvax vaccines with monoclonal antibody therapy could le... patients who had previously been immunized with a gvax vaccine. The new study, a joint effort of Dana-...
GVAX in Medical Technology

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...state Cancer Session) -- Oral presentation beginning at 11:30 a.m. local time on Monday, June 2, 2008. -- "Expanded phase 1 combination trial of gvax immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" (Abstract #5146, Geni...

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

... hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimum...limumab in combination with the Cell Genesys, Inc. gvax immunotherapy for prostate cancer (an investig...nsion cohort (3 mg/kg ipilimumab). The dose of gvax immunotherapy for prostate cancer used in this...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

...ed follow-up data from a Phase 2 clinical trial of gvax immunotherapy for pancreatic cancer which was cond...ients with operable pancreatic cancer who received gvax after surgical resection of their tumor and adjuva...ent surgery and adjuvant therapy without receiving gvax indicated that the median overall survival of the ...
GVAX in Biological News

Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection

...eration and allows both Tregs and Teff cells to proliferate in response to exposure to self-antigen. Interestingly, combination of CLTA4 blockade with gvax selectively primes the anti-tumor Teff cells for action. This led to greater infiltration of Teff cells into the tumor, and eventually to tumor reject...
GVAX in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...n Bavituximab in Prostate Cancer II-54 Cell Genesys Reveals Data of gvax Immunotherapy for Treatment of Prostate Cancer II-54 Bioponic Phyto...to Take Over Rights of a New Marker Technology II-78 Cell Genesys's gvax Prostate Cancer-Treatment Attains FDA's Fast Track Tag II-78 Envisi...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...pril 12-16, 2008 in San Diego: -- "Dendritic and T cell functions in patients with metastatic hormone- refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session) - Oral presentation scheduled for Monday, A...

Cell Genesys to Present at the BIO CEO and Investor Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Webcast Third Quarter 2007 Conference Call

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Present at the BIO Investor Forum

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

...c cancer drug market to more than double by 2016. The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's gvax will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan....

Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...
Other Tags
(Date:5/22/2013)... 2013 The surging growth in specialty ... through marketing claims to compare mattresses often proves a ... a bed blog , offers shoppers faced with this ... their latest article. , Titled “ Mattress Comparison Overview ... guides readers through the basics of innerspring beds as ...
(Date:5/22/2013)... TX (PRWEB) May 22, 2013 ... sustainable practices in the textile industry, today released ... findings demonstrate that organic cotton production dropped 8% ... dramatic than the staggering 37% drop in 2010-11. ... production. , The report, Textile Exchange’s seventh, ...
(Date:5/22/2013)... Dr. Andrew Satlin offers patients with gum disease ... Assisted New Attachment Procedure (LANAP). May is Stroke Awareness Month, ... gum disease and stroke. Periodontal disease is one of the ... is linked to an increased risk for strokes because of ... pockets. , Periodontal disease is essentially an infection of ...
(Date:5/22/2013)... TWITTER: @the_USO & @SesameStreet are proud to ... in the next 6 months! , Today, the ... came together to show their heartfelt thanks to those who currently ... for distribution to our servicemen and women. The group was ... and the USO as well as the success of the ...
(Date:5/22/2013)... CHARLOTTE, (PRWEB) May 22, 2013 The ... fight against muscular dystrophy at the annual Charlotte Muscle ... $300,000 to help Charlotte-area families living with muscle disease. ... this year's event to support MDA families,” said MDA ... heroes who were partnered with a "Buddy" to make ...
Breaking Medicine News(10 mins):Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 2Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 3Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 4Health News:For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment 2Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 2Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 3Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 4Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 5Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2
(Date:5/22/2013)... together in a major new effort to educate the ... Earth,s people with clean water that looms ahead in ... article in the current edition of Chemical & ... Chemical Society (ACS), the world,s largest scientific society. , ... Jerald L. Schnoor, Ph.D., explain that shortages of reliable ...
(Date:5/22/2013)... responsible for legionellosis, an infectious disease that can lead ... has developed a complex method enabling it to camouflage ... these acting against the infectious bacteria. , Research led ... which teams from the National Institute of Health (NIH) ... Barcelona (BSC) have also participated, has described for the ...
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Small but speedy: Short plants live in the evolutionary fast lane 2
Other Contents